Document:

Document

Exhibit 4.6

DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT

Description of Common Stock

General

The Restated Certificate of Incorporation (the “Restated Certificate”) of Huntington Ingalls Industries, Inc. (the “Company,” “us,” “we,” or “our”), as amended, authorizes the issuance of up to 150,000,000 shares of common stock, par value $0.01 per share (“Common Stock”), and up to 10,000,000 shares of preferred stock, par value $0.01 per share (“Preferred Stock”). Our Common Stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended.

Voting Rights

Holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights for the election of directors. Holders of a plurality of the shares entitled to vote in any election of directors may elect all of the directors standing for election.

Dividends

Dividends may be paid on our Common Stock and on any class or series of stock entitled to participate with our Common Stock as to dividends, but only when and as declared by our Board of Directors (“Board”) and only if full dividends on all then-outstanding series of our Preferred Stock for the then current and prior dividend periods have been paid or provided for.

Rights Upon Liquidation

If we liquidate, holders of our Common Stock are entitled to receive all remaining assets available for distribution to stockholders after satisfaction of our liabilities and the preferential rights of any our Preferred Stock that may be outstanding at that time.

Other Rights
The outstanding shares of our Common Stock are fully paid and nonassessable. The holders of our Common Stock do not have any preemptive, conversion or redemption rights.

Preferred Stock

Under the terms of the Restated Certificate, the Board is authorized, subject to any limitations prescribed by law, without stockholder approval, to issue shares of Preferred Stock in one or more series. Each such series of Preferred Stock shall have such powers (including voting powers, full or limited, or no voting powers), and such designations, preferences and relative, participating, optional or other rights and such qualifications limitations or restrictions thereof, if any, as shall be determined by the Board.
The rights, preferences and privileges of holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock which the Company may designate and issue in the future. In addition, the issuance of Preferred Stock could impede the completion of a merger, tender offer or other takeover attempt.

Exhibit 4.6

Other Provisions of Our Restated Certificate and Bylaws and the General Corporation Law of Delaware

Board Vacancies

Under the Restated Certificate, newly created directorships resulting from any increase in the authorized number of directors or any vacancies on the Board resulting from death, resignation, disqualification, removal or other cause shall be filled solely by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board. 
            
Special Meetings

Our Restated Bylaws (the “Bylaws”) provide that special meetings of the stockholders may only be called by the Board, the Chairperson of the Board or the holders of shares representing at least twenty percent of all the shares of our capital stock issued and outstanding and entitled to vote at such meeting.

Bylaw Amendments

Our Restated Certificate provides that the Bylaws may be amended by the affirmative vote of the Board or by the affirmative vote of the holders of a majority of the shares of our capital stock issued and outstanding and entitled to vote at a stockholder meeting.

Advance Notice Provisions

Under our Bylaws, in order for any matter to be considered “properly brought” before an annual or special meeting by a stockholder, stockholders must comply with certain requirements regarding advance notice to the Company.

Action by Written Consent

Under the General Corporation Law of Delaware and our Bylaws, any action required or permitted to be taken by the stockholders of the Company must be taken at a duly called annual or special meeting, unless the Board authorizes such action to be taken by the written consent of the holders of outstanding shares of stock having not less than the minimum voting power that would be necessary to authorize or take such action at a meeting of stockholders at which all shares entitled to vote thereon were present and voted.

Director Liability

The Restated Certificate contains certain provisions permitted under the General Corporation Law of Delaware relating to the liability of directors. The provisions eliminate a director's personal liability for monetary damages for a breach of fiduciary duty, except in certain circumstances involving wrongful acts, such as the breach of a director’s duty of loyalty or acts or omissions which involve intentional misconduct or a knowing violation of law. Further, the Restated Certificate and Bylaws contain provisions to indemnify our directors and officers to the fullest extent permitted by the General Corporation Law of Delaware.

Section 203 of the General Corporation Law of Delaware

We are subject to the provisions of Section 203 of the General Corporation Law of Delaware. Section 203 prohibits a publicly-held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder” is a person 

Exhibit 4.6

who, together with affiliates and associates, owns, or within three years did own, 15% or more of the Company’s voting stock.Exhibit 10.1

 

February 10, 2020

Acuitas Group Holdings, LLC

2120 Colorado Ave.

Suite 230

Santa Monica, CA 90404

 

Attention: Terren Peizer

 

Dear Mr. Peizer:

Reference is hereby made to the following
documents: (i) that certain Securities Purchase Agreement, dated July 3, 2018, by and among BioVie Inc., a Nevada corporation (“BioVie”),
Acuitas Group Holdings, LLC (“Acuitas”), and the other purchasers identified on the signature pages thereto
(the “Initial Securities Purchase Agreement”), (ii) that certain letter agreement dated June 24, 2019 between
BioVie and Acuitas (the “Letter Agreement”), and (iv) that certain Securities Purchase Agreement, dated September
24, 2019 between BioVie and Acuitas (the “Bridge Securities Purchase Agreement”). All capitalized terms used
herein without definition shall have the same meanings herein as such terms have in the Original Securities Purchase Agreement
or the Bridge Securities Purchase Agreement, as applicable.

The purpose of this letter agreement
(this “Extension Agreement”) is to confirm the continued effectiveness of certain conditional waivers under
the Original Securities Purchase Agreement and extend the period during which such conditional waivers may be satisfied by BioVie.
The Board of Directors, based upon the findings and recommendations of the Capital Structure Committee of the Board of Directors,
has determined that such extension is in the best interest of BioVie and its stockholders and will facilitate the ability of BioVie
to raise capital. The parties also seek to clarify the requirements of the 10% OID Convertible Delayed Draw Debenture attached
as Exhibit B to the Bridge Securities Purchase Agreement (the “Debenture”) to better reflect the parties’ intentions
regarding ongoing draws under the Debenture in light of current capital requirements of the Company and market conditions.

In consideration of the foregoing, the
covenants and agreements herein contained, other valuable consideration (the receipt of which is hereby acknowledged) and intending
to be legally bound hereby, BioVie and Acuitas hereby agree as follows:

1.       Extension.
In consideration of the continued mutual efforts of Acuitas and BioVie to raise external capital, each of Acuitas and BioVie hereby
agree that (i) all references in Section 2(a) of the Letter Agreement to “November 30, 2019” shall be modified to refer
to “April 30, 2020” and (ii) the dates set forth in the definition “Availability Period” in the Debenture
reflect the expectations of the parties as of entering into the Bridge Securities Purchase Agreement and that the passing of such
dates or failure to fully exercise any draw rights thereunder by such dates shall not give rise to any claims prior to any such
formal draws in accordance with the Debenture. Each of Acuitas and BioVie hereby irrevocably and unconditionally waives any and
all rights or duties which may have arisen under the Letter Agreement and the Bridge Securities Purchase Agreement from and after
November 30, 2019 to the date hereof,

    	 

    	 

    

solely as a result of such deadline having been exceeded
or such draw dates having been passed and BioVie withdraws that portion of the second draw under the Debenture which shall not
have been satisfied prior to the date hereof, subject to redraw in accordance with the foregoing understanding.

2.       Confirmation
of Post Reverse Split Share Determinations.

(a)       Each
of Acuitas and BioVie hereby agree that as provided in the Letter Agreement and modified by the Bridge Securities Purchase Agreement,
the amount of Transaction Shares referred to in the Letter Agreement, after giving effect to BioVie’s 1:125 reverse split,
shall equal 5,359,832.

3.       Representations
and Warranties of BioVie. BioVie hereby represents and warrants as follows:

(a)       BioVie
has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Letter Agreement
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Letter Agreement by BioVie
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of BioVie and no further action is required by BioVie, the Board of Directors or BioVie’s shareholders in connection herewith
other than in connection with the Required Approvals. This Letter Agreement has been (or upon delivery will have been) duly executed
by BioVie and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of BioVie enforceable
against BioVie in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

(b)       The
execution, delivery and performance by BioVie of this Letter Agreement, the issuance of the Exchange Shares and the consummation
by it of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of BioVie’s
or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the
creation of any Lien upon any of the properties or assets of BioVie or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument (evidencing a BioVie or Subsidiary debt or otherwise) or other understanding to which BioVie or any Subsidiary
is a party or by which any property or asset of BioVie or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which BioVie or a Subsidiary is subject (including federal and state securities laws
and regulations), or by which any property or asset of BioVie or a Subsidiary is bound or affected; except in the case of each
of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(c)       BioVie
is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution,
delivery and performance by BioVie of this Letter Agreement, other than: (i) the filing of a Current Report on Form 8-K following
the execution of this Letter Agreement, (ii) application(s) to each applicable Trading Market for the listing of the Exchange Shares
for trading thereon in the time and manner required thereby, and (iii) such filings as are required to be made under applicable
state securities laws (collectively, the “Required Approvals”).

    -2-

    

    

(d)       The
Exchange Shares are duly authorized and, when issued in accordance herewith, will be duly and validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by BioVie.

(e)       Neither
BioVie nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given,
or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of
the Securities Act and the rules and regulations promulgated thereunder) for soliciting the Exchange. Assuming the representations
and warranties of Acuitas contained herein are true and complete, the Exchange will qualify for the registration exemption contained
in Section 3(a)(9) of the Securities Act.

4.       Representations
and Warranties of Acuitas. Acuitas hereby represents and warrants as follows:

(a)       Acuitas
is an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation
or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and
to consummate the transactions contemplated by this Letter Agreement and otherwise to carry out its obligations hereunder. The
execution and delivery of this Letter Agreement and performance by Acuitas of the transactions contemplated hreby have been duly
authorized by all necessary limited liability company or similar action on the part of Acuitas. This Letter Agreement has been
duly executed by Acuitas, and when delivered by Acuitas, will constitute the valid and legally binding obligation of Acuitas, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

(b)       Neither
Acuitas nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given,
or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of
the Securities Act and the rules and regulations promulgated thereunder) for soliciting the Exchange, and Acuitas will receive
no additional consideration for the Warrant other than the Exchange Shares.

5.       No
Other Amendments or Waivers. Except as expressly set forth herein, this Letter Agreement shall not be deemed to be a waiver,
amendment or modification of any provisions of the Securities Purchase Agreement, or of any right, power or remedy of Acuitas or
the other Purchasers, or constitute a waiver, amendment or modification of any provision of the Securities Purchase Agreement (except
to the extent herein set forth). Except as set forth herein, Acuitas reserves all rights, remedies, powers, or privileges.

6.       Conflicts.
Except as expressly set forth in this Letter Agreement, the terms and provisions of the Securities Purchase Agreement shall continue
unmodified and in full force and effect. In the event of any conflict between this Letter Agreement and the Securities Purchase
Agreement, this Letter Agreement shall control.

7.       Governing
Law; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Letter Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York,
without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Letter Agreement (whether brought against a party hereto or its
respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of

    -3-

    

    

New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of this Letter Agreement), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or
is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to
process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices to it under this Letter Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding
to enforce any provisions of this Letter Agreement, then the prevailing party in such Action or Proceeding shall be reimbursed
by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY
EITHER PARTY AGAINST THE OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE
LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

8.       Notices;
Miscellaneous. Section 5.4 (Notices) of the Original Securities Purchase Agreement shall govern any and all notices or other
communications or deliveries required or permitted to be provided hereunder. Sections 5.6 (Headings), 5.12 (Severability), 5.15
(Remedies), and 5.19 (Construction) of the Original Securities Purchase Agreement are incorporated herein, with each reference
to the “Agreement” or the “Transaction Documents” therein being replaced by a reference to this Letter
Agreement.

9.       Execution.
This Letter Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

(Signature Pages Follow)

 

    -4-

    

    

Kindly acknowledge your acceptance of
this Letter Agreement by executing in the space provided below.

Sincerely,

BIOVIE INC.

By:/s/ Jonathan Adams

Name: Jonathan Adams

Title: President and Chief Operating Officer

Acknowledged and agreed:

ACUITAS GROUP HOLDINGS, LLC

By:/s/ Terren S. Peizer

Name:Terren S. Peizer

Title:Managing Member

 

 

    -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]